[{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"84573df1-6556-4bd1-8122-88ef0fa3cd96","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879978","created_at":"2023-05-30T14:05:15.128Z","updated_at":"2025-02-25T16:33:29.735Z","phase":"Phase 1/2","brief_title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","source_id_and_acronym":"NCT05879978","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obrixtamig (BI 764532) • ezabenlimab (BI 754091)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 09/05/2025","primary_completion_date":" 09/05/2025","study_txt":" Completion: 09/05/2025","study_completion_date":" 09/05/2025","last_update_posted":"2025-02-07"},{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"bce05c4f-6c6a-4884-8079-4fd16c00542d","acronym":"KISIMA-02","url":"https://clinicaltrials.gov/study/NCT05846516","created_at":"2023-05-06T14:04:12.085Z","updated_at":"2024-07-02T16:34:59.526Z","phase":"Phase 1","brief_title":"A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)","source_id_and_acronym":"NCT05846516 - KISIMA-02","lead_sponsor":"Amal Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-03"},{"id":"8684fe35-4cc2-47ff-bb79-45f67ae9a6b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068102","created_at":"2021-10-05T20:00:16.409Z","updated_at":"2024-07-02T16:35:00.041Z","phase":"Phase 1","brief_title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","source_id_and_acronym":"NCT05068102","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063 • BI 770371"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-05-30"},{"id":"6c440b25-6764-4263-b4a4-84f133298de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06091930","created_at":"2023-10-23T20:13:35.686Z","updated_at":"2024-07-02T16:35:06.730Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6","source_id_and_acronym":"NCT06091930","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NCR3LG1","pipe":"","alterations":" ","tags":["NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765049"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 11/13/2026","primary_completion_date":" 11/13/2026","study_txt":" Completion: 02/11/2027","study_completion_date":" 02/11/2027","last_update_posted":"2024-05-01"},{"id":"7b1dfaf8-e8cd-4533-91de-cf52bee69c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT02952248","created_at":"2021-01-18T14:29:57.426Z","updated_at":"2024-07-02T16:35:06.782Z","phase":"Phase 1","brief_title":"A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours","source_id_and_acronym":"NCT02952248","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 11/21/2016","start_date":" 11/21/2016","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2024-04-30"},{"id":"282c5598-a3f1-4e10-8b03-9fef7b6d2b9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468426","created_at":"2021-01-18T17:05:39.851Z","updated_at":"2024-07-02T16:35:11.588Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","source_id_and_acronym":"NCT03468426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 05/03/2018","start_date":" 05/03/2018","primary_txt":" Primary completion: 08/06/2024","primary_completion_date":" 08/06/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-03"},{"id":"dea5532c-b3c0-418a-829d-11fe7b2663af","acronym":"CAR2BRAIN","url":"https://clinicaltrials.gov/study/NCT03383978","created_at":"2021-01-18T16:41:54.714Z","updated_at":"2024-07-02T16:35:12.539Z","phase":"Phase 1","brief_title":"Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma","source_id_and_acronym":"NCT03383978 - CAR2BRAIN","lead_sponsor":"Johann Wolfgang Goethe University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • HER2 t-haNK"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-27"},{"id":"5afb8f35-987a-4b31-ac0f-ac4ece437bab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04752215","created_at":"2022-05-26T22:56:02.452Z","updated_at":"2024-07-02T16:35:13.942Z","phase":"Phase 1","brief_title":"A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface","source_id_and_acronym":"NCT04752215","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NCR3LG1","pipe":"","alterations":" ","tags":["NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765049"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/06/2021","start_date":" 05/06/2021","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-19"},{"id":"96a72c38-5254-4a8a-8d13-048c6238a111","acronym":"EMPIRE","url":"https://clinicaltrials.gov/study/NCT06084689","created_at":"2023-10-16T15:12:55.518Z","updated_at":"2024-07-02T16:35:32.276Z","phase":"Phase 2","brief_title":"Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures","source_id_and_acronym":"NCT06084689 - EMPIRE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1 • TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["PD-L1 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-10-20"},{"id":"e836e839-556f-4146-93d2-b74e4f803dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433898","created_at":"2021-01-18T16:56:19.022Z","updated_at":"2024-07-02T16:35:41.637Z","phase":"Phase 1","brief_title":"This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer","source_id_and_acronym":"NCT03433898","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 02/23/2018","start_date":" 02/23/2018","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 07/20/2023","study_completion_date":" 07/20/2023","last_update_posted":"2023-07-28"},{"id":"c202d09f-4287-4463-8629-079b1034deac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03156114","created_at":"2021-01-18T15:33:42.030Z","updated_at":"2024-07-02T16:35:44.324Z","phase":"Phase 1","brief_title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","source_id_and_acronym":"NCT03156114","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 03/09/2023","primary_completion_date":" 03/09/2023","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-06-29"},{"id":"7bec813b-14cc-42a1-bb04-2fb83e17c553","acronym":"","url":"https://clinicaltrials.gov/study/NCT04653142","created_at":"2021-07-24T16:52:37.044Z","updated_at":"2024-07-02T16:36:10.679Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT04653142","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 04/20/2022","primary_completion_date":" 04/20/2022","study_txt":" Completion: 04/20/2022","study_completion_date":" 04/20/2022","last_update_posted":"2022-05-10"},{"id":"e0f1a0c3-fe9e-435b-955f-31f344df4f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499352","created_at":"2021-01-18T21:33:17.500Z","updated_at":"2024-07-02T16:36:20.753Z","phase":"Phase 2","brief_title":"A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer","source_id_and_acronym":"NCT04499352","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 10/19/2020","primary_completion_date":" 10/19/2020","study_txt":" Completion: 10/19/2020","study_completion_date":" 10/19/2020","last_update_posted":"2021-11-15"}]